BIAF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIAF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
bioAffinity Technologies's EBITDA per Share for the three months ended in Dec. 2023 was $-0.24.
During the past 3 years, the average EBITDA Per Share Growth Rate was 29.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of bioAffinity Technologies was 29.70% per year. The lowest was 29.70% per year. And the median was 29.70% per year.
For the Diagnostics & Research subindustry, bioAffinity Technologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where bioAffinity Technologies's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
bioAffinity Technologies (NAS:BIAF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Thank you for viewing the detailed overview of bioAffinity Technologies's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Roby Joyce | director | 22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257 |
Xavier Trinidad Reveles | officer: Chief Operating Officer | 22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257 |
Michael Philip Dougherty | officer: Chief Financial Officer | 2934 SCATTERED OAKS ST, SAN ANTONIO TX 78232 |
James Michael Edwards | officer: Chief Financial Officer | 30907 KEENELAND DRIVE, FAIR OAKS RANCH TX 78015 |
Peter S Knight | director | 6702 STEIN CIRCLE, #642, P.O. BOX 4138, PARK CITY UT 84060 |
Steven Girgenti | director, officer: Executive Chairman | C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013 |
Robert A. Anderson | director | 70 DOPPLER, IRVINE CA 92618 |
Gary D Rubin | director, 10 percent owner | 2080 NW BOCA RATON BLVD, STE 2, BOCA RATON FL 33431 |
Stuart Diamond | director | 498 SEVENTH AVE, NEW YORK NY 10018 |
Maria Zannes | director, officer: President, CEO | 19702 BELLA LOMA, #6005, SAN ANTONIO TX 78256 |
Harvey Sandler Revocable Trust | 10 percent owner | 21170 N. E. 22ND COURT, NORTH MIAMI BEACH FL 33180 |
Mohsin Y Meghji | director | C/O LOUGHLIN MEGHJI + COMPANY, NEW YORK NY 10016 |
Vivienne I Rebel | officer: EVP, Chief Sci. & Med. Officer | 8922 APACHE TRAIL, SAN ANTONIO TX 78255 |
Timothy P Zannes | officer: Secretary, EVP, Gen. Counsel | 1510 VISTA LARGA CT. NE, ALBUQUERQUE NM 87106 |
Nathan M Perlmutter | 10 percent owner | 28 PARRISH POND LANE, SOUTHAMPTON NY 11968 |
From GuruFocus
By Business Wire • 11-15-2023
By ACCESSWIRE • 01-05-2024
By Business Wire Business Wire • 09-01-2022
By Business Wire Business Wire • 12-01-2022
By Business Wire • 11-06-2023
By Business Wire • 10-10-2023
By Business Wire • 09-19-2023
By Business Wire Business Wire • 12-15-2022
By Business Wire • 11-30-2023
By Business Wire • 11-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.